Barclays raised the firm’s price target on Rapt Therapeutics (RAPT) to $58 from $35 and keeps an Overweight rating on the shares following the company’s update on its chronic spontaneous urticaria program for RPT904. The firm has increased confidence in the RPT904 opportunity following the update, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT:
- RAPT Therapeutics’ Promising Phase 2 Results and Strategic Advancements Drive Buy Rating
- JPMorgan upgrades Rapt Therapeutics on ‘compelling’ CSU data
- Rapt Therapeutics upgraded to Overweight from Neutral at JPMorgan
- RAPT Therapeutics trading resumes
- RAPT Therapeutics trading halted, volatility trading pause